225 related articles for article (PubMed ID: 27613848)
1. Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model.
Ba M; Kong M; Guan L; Yi M; Zhang H
Oncotarget; 2016 Sep; 7(37):58802-58812. PubMed ID: 27613848
[TBL] [Abstract][Full Text] [Related]
2. Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models.
Ba M; Kong M; Ma G
Drug Des Devel Ther; 2015; 9():199-206. PubMed ID: 25565773
[TBL] [Abstract][Full Text] [Related]
3. NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.
Kong M; Ba M; Liu C; Zhang Y; Zhang H; Qiu H
Behav Brain Res; 2015 Apr; 282():46-53. PubMed ID: 25576965
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of repetitive transcranial magnetic stimulation in an animal model of Parkinson's disease.
Lee JY; Kim SH; Ko AR; Lee JS; Yu JH; Seo JH; Cho BP; Cho SR
Brain Res; 2013 Nov; 1537():290-302. PubMed ID: 23998987
[TBL] [Abstract][Full Text] [Related]
5. The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.
Sanz-Blasco S; Bordone MP; Damianich A; Gomez G; Bernardi MA; Isaja L; Taravini IR; Hanger DP; Avale ME; Gershanik OS; Ferrario JE
Mol Neurobiol; 2018 Jun; 55(6):5125-5136. PubMed ID: 28840468
[TBL] [Abstract][Full Text] [Related]
6. Regulation of Pleiotrophin and Fyn in the striatum of rats undergoing L-DOPA-induced dyskinesia.
Gomez G; Saborido MD; Bernardi MA; Gershanik OS; Taravini IR; Ferrario JE
Neurosci Lett; 2018 Feb; 666():5-10. PubMed ID: 29241709
[TBL] [Abstract][Full Text] [Related]
7. Treadmill Exercise Attenuates L-DOPA-Induced Dyskinesia and Increases Striatal Levels of Glial Cell-Derived Neurotrophic Factor (GDNF) in Hemiparkinsonian Mice.
Speck AE; Schamne MG; S Aguiar A; Cunha RA; Prediger RD
Mol Neurobiol; 2019 Apr; 56(4):2944-2951. PubMed ID: 30073506
[TBL] [Abstract][Full Text] [Related]
8. Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson's disease.
Sayın S; Cakmur R; Yener GG; Yaka E; Uğurel B; Uzunel F
J Clin Neurosci; 2014 Aug; 21(8):1373-6. PubMed ID: 24631324
[TBL] [Abstract][Full Text] [Related]
9. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
10. The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
Gil S; Park C; Lee J; Koh H
Cell Mol Neurobiol; 2010 Aug; 30(6):817-25. PubMed ID: 20232137
[TBL] [Abstract][Full Text] [Related]
11. rTMS effects on levodopa induced dyskinesias in Parkinson's disease patients: searching for effective cortical targets.
Koch G
Restor Neurol Neurosci; 2010; 28(4):561-8. PubMed ID: 20714078
[TBL] [Abstract][Full Text] [Related]
12. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
13. Tat-Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa-induced dyskinetic rats model.
Ba M; Yu G; Yang H; Wang Y; Yu L; Kong M
Behav Brain Res; 2019 Jan; 356():41-45. PubMed ID: 30130562
[TBL] [Abstract][Full Text] [Related]
14. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Putterman DB; Munhall AC; Kozell LB; Belknap JK; Johnson SW
J Pharmacol Exp Ther; 2007 Oct; 323(1):277-84. PubMed ID: 17660384
[TBL] [Abstract][Full Text] [Related]
16. CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
Yang X; Zhu Z; Ding X; Wang X; Cui G; Hua F; Xiang J
Brain Res; 2018 May; 1687():66-73. PubMed ID: 29452071
[TBL] [Abstract][Full Text] [Related]
17. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Wang Y; Wang HS; Wang T; Huang C; Liu J
J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
[TBL] [Abstract][Full Text] [Related]
18. Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.
Figge DA; Eskow Jaunarajs KL; Standaert DG
J Neurosci; 2016 Jun; 36(24):6514-24. PubMed ID: 27307239
[TBL] [Abstract][Full Text] [Related]
19. Combination of Human Mesenchymal Stem Cells and Repetitive Transcranial Magnetic Stimulation Enhances Neurological Recovery of 6-Hydroxydopamine Model of Parkinsonian's Disease.
Lee JY; Kim HS; Kim SH; Kim HS; Cho BP
Tissue Eng Regen Med; 2020 Feb; 17(1):67-80. PubMed ID: 31970698
[TBL] [Abstract][Full Text] [Related]
20. Continuous dopaminergic stimulation counteracts L-DOPA-induced overactivity of Ca
Fu J; Zhao X; Tian F; Yu X
Exp Brain Res; 2022 Aug; 240(7-8):1933-1941. PubMed ID: 35699744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
